Lunit Inc.

Many countries have already realized the value of the biotech industry and are now aggressively trying to attract foreign companies in this space. But South Korea needs to up the pace to improve regul

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion

Amid prolonged difficulties in the financing environment this year, South Korean biotech firms including Genexine Inc. and Bridge Biotherapeutics, Inc. have opted to suspend low-priority R&D proje

South Korean bioventure funding remained weak in the third quarter, with venture capital investment in the sector falling further from the previous three months, although a handful of companies manage